United Kingdom (GB)

Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study (2019) Feagan BG, Sandborn WJ, D'Haens GR, Panes J, Kaser A, Ferrante M, Louis E, et al. Conference contribution Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019) Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Conference contribution Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial (2019) Stone J, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial (2019) Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial (2019) Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases (2019) Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, et al. Conference contribution BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo (2019) Ross R, Corinaldesi C, Migneco G, El-Sherbiny Y, Holmes S, Distler J, Mckimmie C, Del Galdo F Conference contribution ABSORB bioresorbable scaffold versus Xience metallic stent in acute coronary syndromes with treated with percutaneous coronary intervention. A subanalysis of the COMPARE-ABSORB trial (2019) Van Geuns RJ, Smits PC, Chang CC, Wlodarczyk A, Chevalier B, West N, Gori T, et al. Conference contribution Impact of chronic kidney disease on efficacy and safety of interventional left atrial appendage closure - results from the prospective multicenter LAARGE registry (2019) Fastner C, Brachmann J, Lewalter T, Zeymer U, Sievert H, Nienaber CA, Weiss C, et al. Conference contribution Prognostic value and incremental benefit of ischaemic myocardial burden subtended by non-invasive CT-derived fractional flow reserve (FFRCT) significant stenoses (2019) Ihdayhid AR, Norgaard BL, Khav N, Gaur S, Leipsic J, Nerlekar N, Osawa K, et al. Conference contribution